Skip to main content

Month: September 2025

Fury Announces Results of Preliminary Economic Assessment for the Eau Claire Gold Deposit with a Base Case After-Tax NPV (5%) of $554M and After-Tax IRR of 41%

Figure 11Eau Claire Resource Long Section Looking North. The inset depicts the improved geometry of modelled veins within the eastern portion of the resource.TORONTO, Sept. 02, 2025 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce results from a preliminary economic assessment (PEA) for the high-grade Eau Claire deposit located in the Eeyou Istchee Territory of the James Bay region of Quebec. The PEA represents an initial conceptual evaluation of the economic potential of Eau Claire’s mineral resources and was prepared in accordance with National Instrument 43-101 (“NI 43-101”) by SGS Geological Services. All dollar amounts are in Canadian dollars unless otherwise specified. Three scenarios, all based on the same mine plan, were evaluated, each returning...

Continue reading

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced the nomination of its lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy designed to significantly reduce LDL cholesterol (LDL-C) levels. “Today’s nomination of EDIT-401 as our lead in vivo development candidate is a significant milestone in our long-term vision to lead the field of in vivo programmable gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President...

Continue reading

Baker Hughes Selected by Fervo Energy to Deliver Geothermal Power Generation Equipment for Innovative New Power Plants

Baker Hughes to design and deliver key equipment for geothermal Organic Rankine Cycle (ORC) power plants at Fervo’s Cape Station Phase II project in Utah Award includes Baker Hughes turboexpander, BRUSH™ Power Generation generator and other related equipmentHOUSTON and LONDON, Sept. 02, 2025 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, announced Tuesday an award from Fervo Energy Company, the leader in next-generation geothermal energy, to design and deliver equipment for five Organic Rankine Cycle (ORC) power plants at Fervo’s Cape Station power generation project near Milford, Utah, United States. Once operational, the five Cape Phase II ORC plants will generate approximately 300 megawatts of clean, reliable, and affordable power to the grid, equivalent power to approximately 180,000...

Continue reading

Playboy to Participate in Lake Street’s Best Ideas Growth Conference

LOS ANGELES, Sept. 02, 2025 (GLOBE NEWSWIRE) — Playboy, Inc. (Nasdaq: PLBY) (the “Company” or “Playboy”), one of the most recognizable and iconic brands in the world, announced today that management will participate in the 9th Annual Lake Street Capital Markets Best Ideas Growth (BIG9) Conference taking place in New York City on September 11, 2025. Ben Kohn, CEO, will be available for one-on-one meetings with attending investors throughout the day. To schedule a one-on-one meeting with management, investors are encouraged to contact their Lake Street representative or reach out to Playboy’s investor relations team at plby@fnkir.com. About Playboy, Inc. Playboy, Inc. is a global pleasure and leisure company connecting consumers with products, content, and experiences that help them lead happier, more fulfilling lives. Playboy is...

Continue reading

Gaming & Leisure Properties Furthers Tribal Partnership With Accretive Long-Term Financing for Caesars Republic Sonoma County

$225 MM FINANCING COMMITMENT AT A BLENDED RATE OF 12.79% A 45-YEAR TERM LEASE OF AT LEAST $112.5 MM AT A 9.75% CAP RATEWYOMISSING, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (“GLPI”) today announced its $225 million commitment to serve as the lead real estate financing partner for a new, integrated resort, Caesars Republic Sonoma County, that will be developed on the site of the current River Rock Casino. Pursuant to its agreements with Caesars Entertainment (NASDAQ: CZR) (“Caesars”) and the Dry Creek Rancheria Band of Pomo Indians (“Dry Creek”), GLPI will initially act as a lender to the project, with a delayed draw term loan of $180 million, priced at a fixed rate of 12.50%, and a term loan B of $45 million, with a current yield to maturity of 13.95%. The blended interest rate...

Continue reading

Transom Capital-Backed Ampure Acquires Power Designers Sibex

LOS ANGELES, Sept. 02, 2025 (GLOBE NEWSWIRE) — Ampure Charging Systems (“Ampure”), a worldwide leader in vehicle charging technology backed by Transom Capital (“Transom”), is pleased to announce its acquisition of Power Designers Sibex (“Power Designers”), a leader in industrial charging products and electronics manufacturing based in Crystal River, Florida. The transaction marks a major milestone in Transom’s ongoing commitment to the revitalization and growth of Ampure’s market-defining industrial charging brand, known as PosiCharge. “Adding Power Designers enhances PosiCharge’s expertise and speed-to-market in product and operations,” said DJ Gregory, President of PosiCharge. “Our commitment to this acquisition underscores our determination to be the very best partner to our customers and a market-leading force in industrial...

Continue reading

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in 3Q 2025 Cash runway extended into 2028SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced it has completed the sale of its China subsidiary to AstraZeneca for a total consideration of approximately $220 million, consisting of $85 million in enterprise value and approximately $135 million in net cash held in China. “We are thrilled to announce the completion of the sale of FibroGen China to AstraZeneca and are...

Continue reading

Hammond Power Solutions Provides Update on U.S. Tariff Changes

GUELPH, Ontario, Sept. 02, 2025 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) has determined that the recently expanded U.S. tariffs on steel and aluminum derivative products apply to certain materials and components included in many of the Company’s products. The Company expects these tariffs to have a relatively uniform impact across its industry and will work collaboratively with its customers and suppliers to manage and offset the effect of these additional costs. Although there may be short-term implications arising from these changes, at this time, the Company does not anticipate that the tariffs will have a material impact on its business. “While this change in trade policy brings complexity and cost to the industry, we have confidence in our adaptable team and in our strong relationships...

Continue reading

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related DiseaseNEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. “We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases,” said Pablo Legorreta, founder and CEO of Royalty Pharma. “There is clear unmet need in IgG4-RD where obexelimab, with its exciting novel B cell modulating mechanism of action, has...

Continue reading

Black Rock Coffee Bar Announces Launch of Initial Public Offering

SCOTTSDALE, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (“Black Rock Coffee Bar”) today announced the launch of the initial public offering of 14,705,882 shares of its Class A common stock. The initial public offering price is currently expected to be between $16.00 and $18.00 per share. Black Rock Coffee Bar expects to grant the underwriters a 30-day option to purchase up to an additional 2,205,882 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. Black Rock Coffee Bar has applied to list its Class A common stock on the Nasdaq Global Market under the ticker symbol “BRCB.” J.P. Morgan, Jefferies, Morgan Stanley and Baird are acting as lead book-running managers for the proposed offering. Stifel and William Blair are acting as additional...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.